These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 20392385)

  • 21. Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?
    Suzuki Y; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Miyakawa Y; Kumada H
    J Gastroenterol Hepatol; 2009 Mar; 24(3):429-35. PubMed ID: 19226381
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Evaluation of a quantitative HBV-DNA PCR assay in lamivudine treated hepatitis B-infected patients].
    Deal C; Ajana F; Canva V; Mouton Y; Yazdanpanah Y; Wattré P; Bocket L
    Ann Biol Clin (Paris); 2002; 60(5):581-8. PubMed ID: 12368144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group.
    Chien RN; Liaw YF; Atkins M
    Hepatology; 1999 Sep; 30(3):770-4. PubMed ID: 10462384
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A 3-year clinical trial of lamivudine in treatment of patients with chronic hepatitis B.
    Yao GB; Cui ZY; Wang BE; Yao JL; Zeng MD
    Hepatobiliary Pancreat Dis Int; 2004 May; 3(2):188-93. PubMed ID: 15138107
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study.
    Serfaty L; Thabut D; Zoulim F; Andreani T; Chazouillères O; Carbonell N; Loria A; Poupon R
    Hepatology; 2001 Sep; 34(3):573-7. PubMed ID: 11526544
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy.
    Yuen MF; Fung J; Seto WK; Wong DK; Yuen JC; Lai CL
    Antivir Ther; 2009; 14(5):679-85. PubMed ID: 19704171
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interferon treatment of anti-HBe positive and HBV DNA positive chronic hepatitis B.
    Alberti A; Fattovich G; Pontisso P; Brollo L; Belussi F; Ruol A
    Chemioterapia; 1988 Dec; 7 Suppl 3():15-9. PubMed ID: 3073869
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels.
    Tseng TC; Liu CJ; Wang CC; Chen PJ; Lai MY; Chen DS; Kao JH
    Antivir Ther; 2009; 14(2):203-10. PubMed ID: 19430095
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B.
    Sherman M; Yurdaydin C; Sollano J; Silva M; Liaw YF; Cianciara J; Boron-Kaczmarska A; Martin P; Goodman Z; Colonno R; Cross A; Denisky G; Kreter B; Hindes R;
    Gastroenterology; 2006 Jun; 130(7):2039-49. PubMed ID: 16762627
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic strategies for chronic hepatitis B virus infection in 2008.
    Khokhar A; Afdhal NH
    Am J Med; 2008 Dec; 121(12 Suppl):S33-44. PubMed ID: 19185073
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT.
    Kumar M; Sarin SK; Hissar S; Pande C; Sakhuja P; Sharma BC; Chauhan R; Bose S
    Gastroenterology; 2008 May; 134(5):1376-84. PubMed ID: 18471514
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of pegylated interferon and lamivudine for patients with chronic hepatitis B who have failed treatment.
    Sarin SK; Kumar M; Hissar S; Sharma BC
    Hepatobiliary Pancreat Dis Int; 2006 Aug; 5(3):374-80. PubMed ID: 16911934
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Chronic hepatitis B: antiviral treatment guidelines].
    Hézode C; Pawlotsky JM
    Rev Prat; 2010 Jun; 60(6):751-8. PubMed ID: 20623887
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pretreatment alanine transaminase level may not be the most important predictor of HBeAg loss in the older patient.
    Lee JI; Park HJ; Lee JW; Kim YS; Jeong S; Lee DH; Kim HG; Shin YW; Kwon KS
    Liver Int; 2009 Feb; 29(2):231-6. PubMed ID: 18637063
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current treatment for chronic hepatitis B in Japan.
    Ohishi W; Chayama K
    Clin J Gastroenterol; 2009 Oct; 2(5):325-330. PubMed ID: 26192607
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of chronic hepatitis B with nucleos(t)ide analogues.
    Ohishi W; Chayama K
    Hepatol Res; 2012 Mar; 42(3):219-25. PubMed ID: 22176139
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Telbivudine: a hepatitis B-specific antiviral.
    Lim SG
    Expert Rev Clin Pharmacol; 2008 Mar; 1(2):217-29. PubMed ID: 24422647
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of hepatitis B in developing countries.
    Abbas Z; Siddiqui AR
    World J Hepatol; 2011 Dec; 3(12):292-9. PubMed ID: 22216369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Performance of two simplified HBV treatment criteria (TREAT-B score and WHO guidelines) in Burkina Faso, West Africa.
    Shimakawa Y; Boucheron P; Luong Nguyen LB; Lemoine M; Sombié R
    J Hepatol; 2019 Oct; 71(4):842-844. PubMed ID: 31331666
    [No Abstract]   [Full Text] [Related]  

  • 40. Improving outcomes for patients with chronic hepatitis B.
    Gish RG
    Hepatol Res; 2007 Jul; 37(s1):S67-78. PubMed ID: 17627639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.